Table 1.

Acylcarnitine concentrations of screened newborns

Acylcarnitines [μmol/l]			C4	C6	C8	C10	C12	C14	C16	C18
Middle Europe	healthy controls (n = 590.216)	median	0.38	0.12	0.10	0.09	0.13	0.21	4.37	0.97
		IQR	0.27	0.14	0.07	0.09	0.09	0.13	2.18	0.52
	MCAD deficiency (n = 63)	median	0.40	1.31	5.14	0.59	0.11	0.19	3.47	0.80
		IQR	0.23	1.27	8.78	0.64	0.10	0.12	1.59	0.46
	VLCAD deficiency (n = 5)	median	0.28	0.11	0.12	0.15	0.47	0.85	3.15	1.38
		IQR	0.11	0.07	0.08	0.13	0.19	0.45	1.04	1.44
South Australia	MCAD deficiency (n = 13)	median	0.32	0.97	7.23	1.10	0.25	0.32	3.49	2.69
		IQR	0.07	0.95	7.27	0.39	0.09	0.13	1.80	1.18
	VLCAD deficiency (n = 3)	median	0.40	0.16	0.15	0.34	1.19	2.41	4.99	3.11
		IQR	0.27	0.08	0.10	0.21	0.42	2.71	3.22	5.43

Summary of regional dissimilarities of acylcarnitines (with even-chain saturated fatty acid acyl group) concentrations (median and interquartile range (IQR)) of newborns screened in Middle Europe and South Australia [28,29].